ASP-3026

N/A

Report date: 2022/07/04 19:38:02

NME

Base Information

Drug NameASP-3026

Drug Alias NameASP-3026

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionAnaplastic lymphoma kinase inhibitors

TargetsAnaplastic lymphoma kinase

Therapy Area/IndicationsSolid tumoursLymphoma, B-CellNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesJapan

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAstellas Pharma Inc

China Registration ClassN/A

Active CompaniesN/A

Active IndicationsN/A

Inactive IndicationsSolid tumoursLymphoma, B-CellNeoplasms

ATC CodeN/A